PharmaResearch Achieves Record-High First-Half Revenue and Operating Profit

PharmaResearch, a regenerative medicine company, has achieved its best-ever performance in the first half of the year, with both revenue and operating profit hitting record highs. The company announced on August 7 that it recorded 324.8 billion won in revenue and 123.8 billion won in operating profit for the first half of 2026 on a consolidated basis.

This remarkable financial achievement is attributed to sustained domestic demand for 'Rejuran,' a medical device utilizing polynucleotide (PN) derived from salmon for facial wrinkle improvement. The company also benefited from a significant increase in exports of its medical devices and cosmetics to European markets.

PharmaResearch's success highlights the growing market for regenerative medicine products and the company's strategic expansion into international markets. The strong performance in the first half sets a positive trajectory for the company's continued growth and innovation in the field.